KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Retained Earnings (2016 - 2025)

Historic Retained Earnings for AbbVie (ABBV) over the last 15 years, with Q3 2025 value amounting to -$14.2 billion.

  • AbbVie's Retained Earnings fell 18674.46% to -$14.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.2 billion, marking a year-over-year decrease of 18674.46%. This contributed to the annual value of -$7.9 billion for FY2024, which is 24273.32% down from last year.
  • AbbVie's Retained Earnings amounted to -$14.2 billion in Q3 2025, which was down 18674.46% from -$11.5 billion recorded in Q2 2025.
  • AbbVie's 5-year Retained Earnings high stood at $5.1 billion for Q1 2022, and its period low was -$14.2 billion during Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$2.5 billion (2024), whereas its average is -$2.5 billion.
  • Its Retained Earnings has fluctuated over the past 5 years, first soared by 25693.92% in 2022, then tumbled by 28822.33% in 2025.
  • Quarter analysis of 5 years shows AbbVie's Retained Earnings stood at $3.1 billion in 2021, then soared by 52.99% to $4.8 billion in 2022, then tumbled by 148.18% to -$2.3 billion in 2023, then tumbled by 242.73% to -$7.9 billion in 2024, then tumbled by 80.18% to -$14.2 billion in 2025.
  • Its Retained Earnings was -$14.2 billion in Q3 2025, compared to -$11.5 billion in Q2 2025 and -$9.5 billion in Q1 2025.